Symphogen
Symphogen A/S, using its proprietary technologies, aims to develop and bring to market target-specific recombinant human polyclonal antibodies known as ‘symphobodies’ which mirror the natural diversity, affinity, and specificity of the human immune response. These products are expected to open an array of treatment opportunities with advantages over current immunoglobulin and monoclonal antibody therapies for the treatment of diseases characterized by complex target antigens such as infectious disease (including biodefense agents), cancer, transplant rejection, and allergy.
Symphogen A/S, using its proprietary technologies, aims to develop and bring to market target-specific recombinant human polyclonal antibodies known as ‘symphobodies’ which mirror the natural diversity, affinity, and specificity of the human immune response. These products are expected to open an array of treatment opportunities with advantages over current immunoglobulin and monoclonal antibody therapies for the treatment of diseases characterized by complex target antigens such as infectious disease (including biodefense agents), cancer, transplant rejection, and allergy.
Proprietary Technology Platform
Symphogen has pioneered symphobody selection and production through its Symplex™ and Sympress™ technology platforms. The Company has a very strong patent position within the field of therapeutic and diagnostic antibodies.
The Symplex technology mirrors the natural immune response by utilizing human starting material for drug lead candidates, which can be monoclonal or polyclonal depending on the nature of the target. The resulting symphobodies maintain the diversity, affinity, and selectivity of human antibodies and potentially improve the safety profile.
The Company employs its Sympress™ technology for production of the selected polyclonal symphobodies. This technology expresses consistent, recombinant polyclonal combinations in unlimited amounts. Symphobodies are expected to be superior to current monoclonal antibodies in the neutralization or elimination of complex target antigens such as those on cancer cells, bacteria, or viruses.
Product Pipeline
Symphogen has plans to develop a range of therapeutics with three products currently in its pipeline. The first is Sym001 (anti-Rhesus D) for treatment of Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of Newborns (HDN). Sym002 (anti-vaccinia virus) targets the adverse events associated with vaccinia virus vaccination against smallpox. This product will target an unmet need within the biodefense arena, since there is a limited supply of therapeutically effective hyperimmune immunoglobulins. Sym003 (anti-RSV) is for the treatment of RSV infection and is expected to show superior efficacy in comparison to existing products. This product has blockbuster potential. In 2005, the Company will focus on developing Sym004 a recombinant human polyclonal antibody against cancer.